Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $60

Benzinga · 05/08 15:54
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $58 to $60.